Pluristem Ltd.

Quick facts

Marketed products

• Cell therapy

Phase 3 pipeline

• PLX-PAD · Regenerative Medicine / Vascular Disease
  PLX-PAD is a placental-derived cell therapy that promotes tissue repair and regeneration through anti-inflammatory and pro-angiogenic mechanisms.

Phase 2 pipeline

• PLX-PAD high doses
• PLX-PAD Low dose

Phase 1 pipeline

• PLX-R18

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Pluristem Ltd. portfolio CI brief
• Pluristem Ltd. pipeline updates RSS